Peer-Reviewed Publications

      Characterization of the Vitrocell® 24/48 aerosol exposure system for its use in exposures to liquid aerosols

      Steiner, S.; Majeed, S.; Kratzer, G.; Vuillaume, G.; Hoeng, J.; Frentzel, S.
      Published
      Apr 27, 2017
      DOI
      10.1016/j.tiv.2017.04.021
      PMID
      28457873
      Link to publication
      Topic
      Summary

      Background: The Vitrocell® 24/48 is an advanced aerosol exposure system that has been widely used and characterized for exposure studies of cigarette smoke, but not for exposure to liquid aerosols with a low gas-vapor phase content such as the ones generated by electronic cigarettes. An experimental system characterization for this specific application was therefore performed. Methods: Glycerol model aerosols of different particle size distributions, produced by a condensation monodisperse aerosol generator, were used for exposing small volumes of phosphate-buffered saline in the Vitrocell® 24/48. Disodium fluorescein, added as a tracer in the aerosol, allowed the exact aerosol mass deposition to be quantified fluorometrically. Results: The aerosol mass delivery efficiency within the system showed variations in the range of +/-25%. Aerosol dilution was not fully reflected in aerosol delivery, the achieved aerosol delivery should therefore be determined experimentally. Quartz crystal microbalances underestimated the deposition of liquid aerosols. Unequal delivery of particles of different sizes was detectable, although this effect is unlikely to be relevant under applied experimental conditions. Conclusions: The Vitrocell® 24/48 aerosol exposure system can be used for exposures to liquid aerosols, such as those generated by electronic cigarettes. However, our results indicate that, compared with aerosol studies of cigarettes, a higher variability is to be expected.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.